E-LIB Suche - Ergebnisse für: Wang-Gillam, Andrea

1

ERBB2 (HER2) amplifications and co-occurring KRAS alteratio..:

Barzi, Afsaneh ; Weipert, Caroline M. ; Espenschied, Carin R....
Frontiers in Oncology. 14 (2024) - p. , 2024

2

Body composition measurements and clinical outcomes in pati..:

Sohal, Davendra P.S. ; Boutin, Robert D. ; Lenchik, Leon...
Journal of Gastrointestinal Surgery. 28 (2024) 3 - p. 232-235 , 2024

Link: https://doi.org/10.1016/..

3

Combined KRAS-MAPK pathway inhibitors and HER2-directed dru..:

Bulle, Ashenafi ; Liu, Peng ; Seehra, Kuljeet...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

4

Defining the KRAS- and ERK-dependent transcriptome in KRAS-..:

Klomp, Jeffrey A. ; Klomp, Jennifer E. ; Stalnecker, Clint A....
Science. 384 (2024) 6700 - p. , 2024

Link: https://doi.org/10.1126/..

5

MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab..:

Kim, Hyun ; Olsen, Jeffrey R. ; Green, Olga L....
International Journal of Radiation Oncology*Biology*Physics. 115 (2023) 1 - p. 214-223 , 2023

Link: https://doi.org/10.1016/..

6

First-in-human phase I/Ib study of NIZ985, a recombinant he..:

Leidner, Rom ; Conlon, Kevin ; McNeel, Douglas G...
Journal for ImmunoTherapy of Cancer. 11 (2023) 10 - p. e007725 , 2023

Link: https://doi.org/10.1136/..

7

Phase 1/1b open-label, dose-escalation study of fruquintini..:

Wang-Gillam, Andrea ; Schelman, William ; Ukrainskyj, Stacey...
Investigational New Drugs. 41 (2023) 6 - p. 851-860 , 2023

Link: https://doi.org/10.1007/..

8

Author Correction: Comprehensive characterization of 536 pa..:

Sun, Hua ; Cao, Song ; Mashl, R. Jay...
Nature Communications. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

9

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Pacl..:

Grierson, Patrick M ; Tan, Benjamin ; Pedersen, Katrina S...
The Oncologist. 28 (2022) 2 - p. e115-e123 , 2022

Link: https://doi.org/10.1093/..

10

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with i..:

Bagegni, Nusayba A. ; Park, Haeseong ; Kraft, Katlyn...
Cancer Chemotherapy and Pharmacology. 89 (2022) 4 - p. 487-497 , 2022

Link: https://doi.org/10.1007/..

11

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine k..:

Pedersen, Katrina S. ; Grierson, Patrick M. ; Picus, Joel...
Investigational New Drugs. 39 (2021) 5 - p. 1298-1305 , 2021

Link: https://doi.org/10.1007/..

12

Phase 1 study combining alisertib with nab-paclitaxel in pa..:

Lim, Kian-Huat ; Opyrchal, Mateusz ; Acharya, Abhi...
European Journal of Cancer. 154 (2021) - p. 102-110 , 2021

Link: https://doi.org/10.1016/..

13

Phase I study of single agent NIZ985, a recombinant heterod..:

Conlon, Kevin ; Watson, Dionysios C ; Waldmann, Thomas A...
Journal for ImmunoTherapy of Cancer. 9 (2021) 11 - p. e003388 , 2021

Link: https://doi.org/10.1136/..

14

Metformin Downregulates PD-L1 Expression in Esophageal Squa..:

Lu, Yao ; Xin, Dao ; Guan, Lulu...
Frontiers in Oncology. 11 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

15

Ablative Five-Fraction Stereotactic Body Radiation Therapy ..:

Hassanzadeh, Comron ; Rudra, Soumon ; Bommireddy, Ani...
Advances in Radiation Oncology. 6 (2021) 1 - p. 100506 , 2021

Link: https://doi.org/10.1016/..